ipragliflozin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| sodium glucose co-transporter inhibitors, phlorizin derivatives | 4890 | 761423-87-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 17, 2014 | PMDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cerebral infarction | 54.34 | 38.15 | 17 | 445 | 45659 | 79698267 |
| Diabetes mellitus inadequate control | 41.66 | 38.15 | 12 | 450 | 24252 | 79719674 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A10BK05 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Sodium-glucose co-transporter 2 (SGLT2) inhibitors |
| MeSH PA | D007004 | Hypoglycemic Agents |
| MeSH PA | D000077203 | Sodium-Glucose Transporter 2 Inhibitors |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
| Diabetes mellitus type 1 | indication | 46635009 | DOID:9744 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.62 | acidic |
| pKa2 | 13.26 | acidic |
| pKa3 | 13.7 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium/glucose cotransporter 2 | Transporter | INHIBITOR | IC50 | 8.13 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Sodium/glucose cotransporter 1 | Transporter | IC50 | 5.73 | SCIENTIFIC LITERATURE | |||||
| Sodium/glucose cotransporter 2 | Transporter | INHIBITOR | IC50 | 8.20 | IUPHAR | ||||
| Sodium/glucose cotransporter 1 | Transporter | INHIBITOR | IC50 | 5.86 | IUPHAR | ||||
| Sodium/glucose cotransporter 1 | Transporter | INHIBITOR | IC50 | 5.93 | IUPHAR | ||||
| Sodium/glucose cotransporter 2 | Transporter | INHIBITOR | IC50 | 8.25 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 3N2N8OOR7X | UNII |
| D10196 | KEGG_DRUG |
| 951382-34-6 | SECONDARY_CAS_RN |
| C3492889 | UMLSCUI |
| CHEBI:134724 | CHEBI |
| CHEMBL2018096 | ChEMBL_ID |
| 10453870 | PUBCHEM_CID |
| DB11698 | DRUGBANK_ID |
| CHEMBL4297658 | ChEMBL_ID |
| 9258 | INN_ID |
| C572941 | MESH_SUPPLEMENTAL_RECORD_UI |
| 9394 | IUPHAR_LIGAND_ID |
Pharmaceutical products:
None